CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2007-12-21): Long-term peginterferon shows promise against hepatitis B in pilot study

Clinical

Long-term peginterferon shows promise against hepatitis B in pilot study

Last Updated: 2007-12-21 12:44:24 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Sixty weeks of treatment with pegylated interferon alfa-2a appears to produce a higher rate of sustained virologic response in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B than that usually achieved with the standard treatment duration of 48 weeks. The study is reported in the December issue of the American Journal of Gastroenterology.

There is a high rate of relapse when conventional interferon or peginterferon are given for 48 weeks, but higher rates of lasting response have been seen when conventional interferon is given for 2 years, note Dr. Robert Perrillo at Baylor University Medical Center in Dallas Texas, and colleagues.

The researchers therefore undertook a pilot study with 13 patients to evaluate the virologic effectiveness of a 60-week course of treatment with peginterferon. They also explored the effectiveness of combination therapy using lamivudine.

The primary end point was sustained virologic response, which was defined as hepatitis B virus DNA less than 20,000 copies/mL and a decrease from baseline in HBV DNA of at least 2 log copies/mL.

Seven of the 13 patients were randomized to receive peginterferon alfa-2a only for 60 weeks, and the other six received the same course of peginterferon, plus lamivudine from weeks 13 through 60. All 13 patients were followed for at least 24 weeks post-treatment.

By the end of treatment, only one patient in each group had not achieved a sustained virologic response. As of the end of the follow-up period (week 84), 5 of 7 (71%) treated with peginterferon monotherapy and 3 of 6 (50%) treated with the combination therapy met the criteria for a sustained virologic response.

The overall 62% sustained virologic response rate in this study compares with a response rate of 42% seen in a recent similar trial of a 48-week regimen, Dr. Perrillo and colleagues point out.

They call for larger randomized, controlled trials to study the effectiveness of peginterferon against HBeAg-negative chronic hepatitis B, with post-treatment follow-up of up to 5 years.

Am J Gastroenterol 2007;102:2718-2723

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.